DualityBio/BioNTech’s ADC Takes on Enhertu In Chemo-Naive HER2-Low Breast Cancer

narrowing window of time
time running out for fast-followers of Enhertu to prove themselves in chemo-free HER2-low breast cancer • Source: Shutterstock

More from China

More from Focus On Asia